Proteasome inhibitors and modulators of angiogenesis in Multiple Myeloma

Current Medicinal Chemistry

Volumn 18, Issue 34, 2011, Pages 5185-5195

  Ferrarini, M ^a   Ferrero, E ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Angiogenesis; Anti angiogenic therapies; Bone marrow microenvironment; Hypoxia; Immunomodulatory drugs; Multiple Myeloma; Proteasome inhibitors

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; POMALIDOMIDE; THALIDOMIDE;

ANGIOGENESIS; DRUG TARGETING; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 82255169321     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798184316     Document Type: Review

References (152)

1. Palumbo, A.; Anderson, K. Multiple Myeloma. N. Engl. J. Med., 2011, 364, 1046-60.
2. Hideshima, T.; Mitsiades, C.; Tonon, G.; Richardson, P. G.; Anderson, K. C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer, 2007, 7, 585-98. (Pubitemid 47106630)
3. Chapman, M. A.; Lawrence, M. S.; Keats, J. J.; Cibulskis, K.; Sougnez, C.; Schinzel, A. C.; Harview, C. L.; Brunet, J. P.; Ahmann, G. J.; Adli, M.; Anderson, K. C.; Ardlie, K. G.; Auclair, D.; Baker, A., Bergsagel, P. L.; Bernstein, B. E.; Drier, Y.; Fonseca, R.; Gabriel, S. B.; Hofmeister, C. C., Jagannath, S.; Jakubowiak, A. J., Krishnan, A.; Levy, J.; Liefeld, T.; Lonial, S.; Mahan, S.; Mfuko, B.; Monti, S.; Perkins, L. M.; Onofrio, R.; Pugh, T. J.; Rajkumar, S. V.; Ramos, A. H.; Siegel, D. S.; Sivachenko, A.; Stewart, A. K.; Trudel, S.; Vij, R.; Voet, D.; Winckler, W.; Zimmerman, T.; Carpten, J.; Trent, J.; Hahn, W. C.; Garraway, L. A.; Meyerson, M.; Lander, E. S.; Getz, G.; Golub, T. R. Initial genome sequencing and analysis of multiple myeloma. Nature, 2011, 471, 467-72.
4. Fukumura, D.; Xavier, R.; Sugiura, T.; Chen, Y.; Park, E. C.; Lu, N., Selig, M.; Nielsen, G.; Taksir, T.; Jain, R. K.; Seed, B. Tumor induction of VEGF promoter activity in stromal cells. Cell, 1998, 94, 715-25. (Pubitemid 28436004)
5. Dvorak, H. F.; Weaver, V. M.; Tlsty, T. D.; Bergers, G. Tumor microenvironment and progression. J. Surg. Oncol., 2011, 103, 468-74.
6. Alsayed, Y.; Ngo, H.; Runnels, J.; Leleu, X.; Singha, U. K.; Pitsillides, CM.; Spencer, J. A.; Kimlinger, T.; Ghobrial, J. M.; Jia, X.; Lu, G.; Timm, M., Kumar, A.; Côté, D.; Veilleux, I.; Hedin, K. E.; Roodman, G. D.; Witzig, T. E.; Kung, A. L.; Hideshima, T.; Anderson, K. C.; Lin, C. P., Ghobrial, I. M. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood, 2007, 109, 2708-17. (Pubitemid 46482062)
7. Burger, J. A.; Ghia, P.; Rosenwald, A.; Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood, 2009, 114, 3367-75.
8. Harrison, J. S.; Rameshwar, O.; Chang, V.; Bandari, P. Oxygen saturation in the bone marrow of healty volunteers. Blood, 2002, 99, 394.
9. Colla, S.; Storti, P.; Donofrio, G.; Todoerti, K.; Bolzoni, M.; Lazzaretti, M.; Abeltino, M.; Ippolito, L.; Neri, A.; Ribatti, D.; Rizzoli, V.; Martella, E.; Giuliani N. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138 (+) cells. Leukemia, 2010, 24, 1967-70.
10. Ceradini, D. J.; Kulkarni, A. R.; Callaghan, M. J.; Tepper, O. M.; Bastidas, N.; Kleinman, M. E.; Caplan, J. M.; Galiano, R. D.; Levine, J. P.; Gurtner, G. C. Nat. Med., 2004, 10, 858-64.
11. Li, Z.; Rich, J. N. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr. Top. Microbiol. Immunol. 2010, 345, 21-30.
12. Le, Q. T.; Denko, N. C.; Giaccia, A. J. Hypoxic gene expression and metastasis. Cancer Metastasis Rev., 2004, 23, 293-310. (Pubitemid 38881813)
13. Martin, S. K.; Diamond, P.; Gronthos, S.; Peet, D. J., Zannettino, A. C. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia, 2011 [Epub ahead of print]
14. Semenza, G. L. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med, 2003, 54, 17-28. (Pubitemid 37386383)
15. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-57.
16. Moserle, L.; Amadori, A.; Indraccolo, S. The angiogenic switch: Implications in the regulation of tumor dormancy. Curr. Mol. Med, 2009, 9, 935-941.
17. Ramanujan, S.; Koenig, G. C.; Padera, T. P.; Stoll, B. R.; Jain, R. K. Local imbalance of proangiogenicand antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res., 2000, 60, 1442-1448. (Pubitemid 30152019)
18. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 2003, 3, 401-410. (Pubitemid 37328844)
19. Pugh, C. W.; Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med, 2003, 9, 677-684. (Pubitemid 36749216)
20. Semenza, G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol, 2002, 64, 993-998. (Pubitemid 35232274)
21. Kallio, P. J.; Wilson, W. J.; O'Brien, S.; Makino, Y.; Poellinger, L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitinproteasome pathway. J. Biol. Chem., 1999, 274, 6519-6525. (Pubitemid 29111068)
22. Leung, D. W.; Cachianes, G.; Kuang, W. J.; Goeddel, D. V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989, 246, 1306-9. (Pubitemid 20066716)
23. Maglione, D.; Guerriero, V.; Viglietto, G.; Delli-Bovi, P.; Persico, M. G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. U S A, 1991, 88, 9267-71. (Pubitemid 21915612)
24. Fahmy, R. G.; Dass, C. R.; Sun, L. Q.; Chesterman, C. N.; Khachigian, L. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat. Med., 2003, 9, 1026-32. (Pubitemid 37021782)
25. Okada, M.; Matsumori, A.; Ono, K.; Miyamoto, T.; Takahashi, M.; Sasayama, S. Hepatocyte growth factor is a major mediator in heparininduced angiogenesis. Biochem. Biophys. Res. Commun., 1999, 255, 80-7. (Pubitemid 29292068)
26. Vacca, A.; Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia, 2006, 20, 193-9. (Pubitemid 43148652)
27. Lafleur, M. A.; Handsley, M. M.; Edwards, D. R. Metalloproteinases and their inhibitors in angiogenesis. Expert Rev. Mol. Med, 2003, 5, 1-39.
28. Rodriguez-Manzaneque, J. C.; Lane, T. F.; Ortega, M. A.; Hynes, R. O.; Lawler, J.; Iruela-Arispe, M. L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U S A, 2001, 98, 12485-90. (Pubitemid 33019972)
29. O'Reilly, M. S. The preclinical evaluation of angiogenesis inhibitors. Invest. New Drugs, 1997, 15, 5-13. (Pubitemid 27217747)
30. Ribatti, D. Endogenous inhibitors of angiogenesis: a historical review. Leuk. Res., 2009, 33, 638-44.
31. Ferrero, E.; Scabini, S.; Magni, E.; Foglieni, C.; Belloni, D.; Colombo, B.; Curnis, F.; Villa, A.; Ferrero, M. E.; Corti, A. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J., 2004, 18, 554-6.
32. Belloni, D.; Scabini, S.; Foglieni, C.; Veschini, L.; Giazzon, A.; Colombo, B.; Fulgenzi, A.; Helle, K. B.; Ferrero, M. E.; Corti, A.; Ferrero, E. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J., 2007, 21, 3052-62. (Pubitemid 47565526)
33. Saharinen, P.; Eklund, L.; Miettinen, J.; Wirkkala, R.; Anisimov, A.; Winderlich, M.; Nottebaum, A.; Vestweber, D.; Deutsch, U.; Koh, G. Y.; Olsen, B. R.; Alitalo, K. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat. Cell Biol., 2008, 10, 527-37. (Pubitemid 351627372)
34. Eilken, H. M.; Adams, R. H. Dynamics of endothelial cell behaviour in sprouting angiogenesis. Curr. Opin. Cell Biol., 2010, 22, 617-25.
35. Carmeliet, P.; De Smet, F.; Loges, S.; Mazzone, M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat. Rev. Clin. Oncol., 2009, 6, 315-26.
36. Hellström, M.; Phng, L. K.; Hofmann, J. J.; Wallgard, E.; Coultas, L.; Lindblom, P.; Alva, J.; Nilsson, A. K.; Karlsson, L.; Gaiano, N.; Yoon, K.; Rossant, J.; Iruela-Arispe, M. L.; Kalén, M.; Gerhardt, H.; Betsholtz, C. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature, 2007, 445, 776-80. (Pubitemid 46279716)
37. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med., 1986, 315, 1650-1659. (Pubitemid 17052899)
38. Nolan, D. J.; Ciarrocchi, A.; Mellick, A. S.; Jaggi, J. S.; Bambino, K.; Gupta, S.; Heikamp, E.; McDevitt, M. R.; Scheinberg, D. A.; Benezra, R.; Mittal, V. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev., 2007, 21, 1546-58. (Pubitemid 46955726)
39. Peters, B. A.; Diaz, L. A.; Polyak, K.; Meszler, L.; Romans, K.; Guinan, E. C.; Antin, J. H.; Myerson, D.; Hamilton, S. R.; Vogelstein, B.; Kinzle, K. W.; Lengauer, C. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med., 2005, 11, 261-2. (Pubitemid 40460552)
40. Döme, B.; Hendrix, M. J.; Paku, S.; Tóvári, J.; Tímár, J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am. J. Pathol., 2007, 170, 1-15. (Pubitemid 47339184)
41. Sharma, P. S.; Sharma, R.; Tyagi, T. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr. Cancer Drug Targets, 2011, 11, 624-53.
42. Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer, 2008, 8, 592-603.
43. Ellis, L. M.; Hicklin, D. J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin. Cancer Res., 2008, 14, 6371-5.
44. Squadrito, M. L.; De Palma, M. Macrophage regulation of tumor angiogenesis: Implications for cancer therapy. Mol. Asp. Med., 2011, 32, 123-45.
45. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005, 307, 58-62. (Pubitemid 40093472)
46. Goel, S.; Duda, D. G.; Xu, L.; Munn, L. L.; Boucher, Y.; Fukumura, D.; Jain, R. K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev., 2011, 91, 1071-121.
47. Ribatti, D.; Scavelli, C., Roccaro, A. M., Crivellato, E.; Nico, B.; Vacca, A. Hematopoietic cancer and angiogenesis. Stem Cells Dev., 2004, 13, 484-495. (Pubitemid 39473579)
48. Munshi, N. C.; Wilson, C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin. Oncol., 2001, 28, 565-569. (Pubitemid 33134415)
49. Rajkumar, S. V.; Mesa, R. A.; Fonseca, R.; Schroeder, G.; Plevak, M. F.; Dispenzieri, A.; Lacy, M. Q.; Lust, J. A.; Witzig, T. E., Gertz, M. A.; Kyle, R. A., Russell, S. J., Greipp, P. R. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin. Cancer Res., 2002, 8, 2210-2216. (Pubitemid 34753592)
50. Pour, L.; Svachova, H.; Adam, Z.; Almasi, M.; Buresova, L.; Buchler, T.; Kovarova, L.; Nemec, P.; Penka, M.; Vorlicek, J.; Hajek, R. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann. Hematol., 2010, 89, 385-9.
51. Di Raimondo, F. Angiogenesis in hematology: a field of active research. Leuk. Res., 2003, 27, 571-3.
52. Pellegrino, A.; Ria, R.; Di Pietro, G.; Cirulli, T.; Surico, G.; Pennisi, A.; Morabito, F.; Ribatti, D.; Vacca, A. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediates interactions with plasma cells. B r. J. Haematol., 2005, 129, 248-256. (Pubitemid 40562446)
53. Anargyrou, K.; Terpos, E.; Vassilakopoulos, T. P.; Pouli, A.; Sachanas, S.; Tzenou, T.; Masouridis, S.; Christoulas, D.; Angelopoulou, M. K.; Dimitriadou, E. M.; Kalpadakis, C.; Tsionos, K.; Panayiotidis, P.; Dimopoulos, M. A.; Pangalis, G. A.; Kyrtsonis, M. C. Greek Myeloma Study Group. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica, 2008, 93, 451-4. (Pubitemid 351398649)
54. Terpos, E.; Anargyrou, K.; Katodritou, E.; Kastritis, E.; Papatheodorou, A.; Christoulas, D.; Pouli, A.; Michalis, E.; Delimpasi, S.; Gkotzamanidou, M.; Nikitas, N.; Koumoustiotis, V.; Margaritis, D.; Tsionos, K.; Stefanoudaki, E.; Meletis, J.; Zervas, K.; Dimopoulos, M. A., on behalf of the Greek Myeloma Study Group, Greece. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. Int. J. Cancer, 2011. [Epub ahead of print]
55. Bellamy, W. T.; Richter, L., Frutiger, Y.; Grogan, T. M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res., 1999, 59, 728-33. (Pubitemid 29076074)
56. Dankbar, B.; Padró, T., Leo, R.; Feldmann, B.; Kropff, M.; Mesters, R. M.; Serve, H.; Berdel, W. E.; Kienast, J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood, 2000, 95, 2630-6. (Pubitemid 30210543)
57. Hose, D.; Moreaux, J.; Meissner, T.; Seckinger, A.; Goldschmidt, H.; Benner, A.; Mahtouk, K.; Hillengass, J.; Rème, T.; De Vos, J.; Hundemer, M.; Condomines, M.; Bertsch, U.; Rossi, J. F., Jauch, A., Klein, B., Möhler, T. Induction of angiogenesis by normal and malignant plasma cells. Blood, 2009, 114, 128-43.
58. Zhang, J.; Sattler, M.; Tonon, G.; Grabher, C.; Lababidi, S.; Zimmerhackl, A.; Raab, M. S.; Vallet, S.; Zhou, Y.; Cartron, M. A.; Hideshima, T.; Tai, Y. T.; Chauhan, D.; Anderson, K. C.; Podar, K. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res., 2009, 69, 5082-5090.
59. Asosingh, K.; De Raeve, H., de Ridder, M., Storme, G. A.; Willems, A.; Van Riet, I, Van Camp, B.; Vanderkerken, K. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica, 2005, 90, 810-7. (Pubitemid 40897223)
60. Vacca, A.; Ria, R.; Semeraro, F.; Merchionne, F.; Coluccia, M., Boccarelli, A.; Scavelli, C.; Nico, B.; Gernone, A.; Battelli, F.; Tabilio, A.; Guidolin, D.; Petrucci, M. T.; Ribatti, D.; Dammacco, F. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood, 2003, 102, 3340-8. (Pubitemid 37314776)
61. Ria, R.; Todoerti, K.; Berardi, S.; Coluccia, A. M. L.; De Luisi, A.; Mattioli, M.; Ronchetti, D.; Morabito, F.; Guarini, A.; Petrucci, M. T.; Dammacco, F.; Ribatti, D.; Neri, A.; Vacca, A. Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma. Clin. Cancer Res., 2009, 15, 5369-5378.
62. Jakob, C.; Sterz, J.; Zavrski, I.; Heider, U.; Kleeberg, L.; Fleissner, C.; Kaiser, M.; Sezer, O. Angiogenesis in multiple myeloma. Eur. J. Cancer, 2006, 42, 1581-90. (Pubitemid 44118769)
63. Wang, X.; Zhang, Z.; Yao, C. Angiogenic activity of mesenchymal stem cells in multiple myeloma. Cancer Invest, 2011, 29, 37-41.
64. Tanaka, Y.; Abe, M.; Hiasa, M.; Oda, A.; Amou, H.; Nakano, A.; Takeuchi, K.; Kitazoe, K.; Kido, S.; Inoue, D.; Moriyama, K.; Hashimoto, T.; Ozaki, S.; Matsumoto, T. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin. Cancer Res., 2007, 13, 816-23. (Pubitemid 46340354)
65. Ribatti, D.; Vacca, A. The role of monocytes-macrophages in vasculogenesis in multiple myeloma. Leukemia, 2009, 23, 1535-1536.
66. Chen, H.; Campbell, R. A.; Chang, Y.; Li, M.; Wang, C. S.; Li, J.; Sanchez, E.; Share, M.; Steinberg, J.; Berenson, A.; Shalitin, D.; Zeng, Z.; Gui, D.; Perez-Pinera, P.; Berenson, R. J.; Said, J.; Bonavida, B.; Deuel, T. F.; Berenson, J. R. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood, 2009, 113, 1992-2002.
67. Zhang, H.; Vakil, V.; Braunstein, M.; Smith, E. L.; Maroney, J.; Chen, L.; Dai, K.; Berenson, J. R.; Hussain, M. M.; Klueppelberg, U.; Norin, A. J.; Akman, H. O.; Ozçelik, T.; Batuman, OA. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005, 105, 3286-94.
68. Ria, R.; Piccoli, C.; Cirulli, T.; Falzetti, F.; Mangialardi, G.; Guidolin, D.; Tabilio, A.; Di Renzo, N.; Guarini, A.; Ribatti, D.; Dammacco, F.; Vacca, A. Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma. Clin Cancer Res, 2008, 14, 1678-85. (Pubitemid 351469451)
69. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A., Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med., 2003, 348, 2609-17. (Pubitemid 36741588)
70. Ruschak, A. M.; Slassi, M.; Kay, L. E.; Schimmer, A. D. Novel Proteasome Inhibitors to Overcome Bortezomib Resistance. J. Natl. Cancer Inst, 2011, May 23. [Epub ahead of print]
71. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 2004, 5, 417-21. (Pubitemid 38610244)
72. Xu, C.; Bailly-Maitre, B.; Reed, J. C. Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest, 2005, 115, 2656-2664. (Pubitemid 41434389)
73. Zhang, K.; Kaufman, R. J. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology, 2006, 66(2 Suppl 1), S102-9. (Pubitemid 43739994)
74. Cenci, S.; Sitia, R. Managing and exploiting stress in the antibody factory. FEBS Lett, 2007, 581, 3652-3657. (Pubitemid 47081003)
75. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V. J.; Elliott, P. J.; Adams, J.; Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res., 2001, 61, 3071-6. (Pubitemid 32691956)
76. Karin, M.; Cao, Y.; Greten, F. R.; Li, Z. W. NF-kB in cancer: From innocent bystander to major culprit. Nat. Rev. Cancer, 2002, 2, 301-310. (Pubitemid 37328783)
77. Shah, J. J.; Orlowski, R. Z. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia, 2009, 23, 1964-79.
78. Hideshima, T.; Anderson, K. C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer, 2002, 2, 927-37. (Pubitemid 37328894)
79. Podar, K.; Raab, M. S.; Tonon, G.; Sattler, M.; Barilà, D.; Zhang, J.; Tai, Y. T.; Yasui, H.; Raje, N.; DePinho, RA.; Hideshima, T.; Chauhan, D.; Anderson K. C. Up-regulation of c-Jun. inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res., 2007, 67, 1680-8. (Pubitemid 46383394)
80. Nerini-Molteni S, Ferrarini M, Cozza S, Caligaris-Cappio F, Sitia R. Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br. J. Haematol, 2008, 14, 494-503. (Pubitemid 351550556)
81. Lee, A. H.; Iwakoshi, N. N.; Anderson, K. C.; Glimcher, L. H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. U S A, 2003, 100, 9946-51. (Pubitemid 37087048)
82. Obeng, E. A.; Carlson, L. M.; Gutman, D. M.; Harrington, W. J. Jr.; Lee, K. P.; Boise, L. H. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Blood, 2006, 107, 4907-16.
83. Bianchi, G.; Oliva, L.; Cascio, P.; Pengo, N.; Fontana, F.; Cerruti, F.; Orsi, A.; Pasqualetto, E.; Mezghrani, A.; Calbi, V.; Palladini, G.; Giuliani, N.; Anderson, K. C.; Sitia, R.; Cenci, S. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood, 2009, 113, 3040-9.
84. David, E.; Kaufman, J. L.; Flowers, C. R.; Schafer-Hales, K.; Torre, C.; Chen, J.; Marcus, A. I.; Sun, S. Y.; Boise, L. H.; Lonial, S. Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood, 2010, 116, 5285-8.
85. Hideshima, T.; Chauhan, D.; Hayashi, T.; Akiyama, M.; Mitsiades, N.; Mitsiades, C.; Podar, K.; Munshi N. C.; Richardson, P. G., Anderson, K. C. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene, 2003, 22, 8386-93. (Pubitemid 37523890)
86. Spisek, R.; Charalambous, A.; Mazumder, A.; Vesolek, D. H.; Jagannath, S.; Dhodapkar, M. V. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood, 2007, 109, 4839-45. (Pubitemid 46827780)
87. Nencioni, A.; Schwarzenberg, K.; Brauer, K. M.; Schmidt, S. M.; Ballestrero, A.; Grunebach, F.; Brossart, P. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood, 2006, 108, 551-558. (Pubitemid 44061355)
88. Nencioni, A.; Garuti, A.; Schwarzenberg, K.; Cirmena, G.; Dal, B. G.; Rocco, I.; Barbieri, E.; Brossart, P.; Patrone, F.; Ballestrero, A. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur. J. Immunol, 2006, 36, 681-689.
89. Jinushi, M.; Vanneman, M.; Munshi, N. C.; Tai, Y. T.; Prabhala, R. H.; Ritz, J.; Neuberg, D.; Anderson, K. C.; Carrasco, D. R.; Dranoff, G. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc. Natl. Acad. Sci. U S A, 2008, 105, 1285-90. (Pubitemid 351397045)
90. Girlanda, S.; Fortis, C.; Belloni, D.; Ferrero, E.; Ticozzi, P.; Sciorati, C.; Tresoldi, M.; Vicari, A.; Spies, T.; Groh, V.; Caligaris-Cappio, F.; Ferrarini, M. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res., 2005, 65, 7502-8. (Pubitemid 41161286)
91. Bauer, S.; Groh, V.; Wu, J.; Steinle, A.; Phillips, J. H.; Lanier, L. L.; Spies, T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science, 1999, 285, 727-9.
92. Das, H.; Groh, V.; Kuijl, C.; Sugita, M.; Morita, C. T.; Spies, T.; Bukowski, J. F. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity, 2001, 15, 83-93. (Pubitemid 32728322)
93. Niedermann, G.; Geier, E.; Lucchiari-Hartz, M.; Hitziger, N.; Ramsperger, A.; Eichmann, K. The specificity of proteasomes: impact on MHC class I processing and presentation of antigens. Immunol. Rev, 1999, 172, 29-48. (Pubitemid 30000467)
94. Ferrarini, M.; Ferrero, E.; Dagna, L.; Poggi, A.; Zocchi, M. R. Human γδ T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol, 2002, 23, 14-17.
95. Hayday, A. C. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity, 2009, 31, 184-96.
96. Shi, J.; Tricot, G. J.; Garg, T. K.; Malaviarachchi, PA.; Szmania, S. M.; Kellum, R. E.; Storrie, B.; Mulder, A.; Shaughnessy, J. D. Jr; Barlogie, B.; van Rhee, F. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Bllood, 2008, 111, 1309-1317. (Pubitemid 351213417)
97. Basler, M.; Lauer, C.; Beck, U.; Groettrup, M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J. Immunol, 2009, 183, 6145-6150.
98. Chanan-Khan, A.; Sonneveld, P.; Schuster, M. W.; Stadtmauer, E. A.; Facon, T.; Harousseau, J. L.; Ben-Yehuda, D.; Lonial, S.; Goldschmidt, H.; Reece, D.; Neuwirth, R.; Anderson, K. C.; Richardson. PG. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J. Clin. Oncol. 2008, 26, 4784-90.
99. LeBlanc, R.; Catley, L. P.; Hideshima, T.; Lentzsch, S.; Mitsiades, C. S.; Mitsiades, N.; Neuberg, D.; Goloubeva, O.; Pien, C. S.; Adams, J.; Gupta, D.; Richardson, P. G.; Munshi, NC.; Anderson, K. C. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res., 2002, 62, 4996-5000. (Pubitemid 34984425)
100. Hamner, J. B.; Dickson, P. V.; Sims, T. L.; Zhou, J.; Spence, Y.; Ng, C. Y.; Davidoff, A. M. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery, 2007, 142, 185-191. (Pubitemid 47198675)
101. Roccaro, A. M.; Hideshima, T.; Raje, N.; Kumar, S.; Ishitsuka, K.; Yasui, H.; Shiraishi, N.; Ribatti, D.; Nico, B.; Vacca, A., Dammacco F., Richardson, P. G.; Anderson, K. C. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res., 2006, 66, 184-91. (Pubitemid 43166024)
102. Hayashi, T.; Hideshima, T.; Anderson, K. C. Novel therapies for multiple myeloma. Br. J. Haematol., 2003, 120, 10-7. (Pubitemid 36056903)
103. Hideshima, T.; Chauhan, D.; Podar, K.; Schlossman, R. L.; Richardson, P.; Anderson, K. C. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin. Oncol., 2001, 28, 607-12. (Pubitemid 33134420)
104. Shin, D. H.; Chun, Y. S.; Lee, D. S.; Huang, L. E.; Park, J. W. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood, 2008, 111, 3131-6.
105. Podar, K.; Shringarpure, R.; Tai, Y. T.; Simoncini, M.; Sattler, M.; Ishitsuka, K.; Richardson, P. G.; Hideshima, T.; Chauhan, D.; Anderson, K. C. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res., 2004, 64, 7500-6. (Pubitemid 39372094)
106. Drexler, H. C.; Risau, W.; Konerding, M. A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J., 2000, 14, 65-77. (Pubitemid 30051524)
107. Veschini, L.; Belloni, D.; Foglieni, C.; Cangi, M. G.; Ferrarini, M.; Caligaris-Cappio, F.; Ferrero, E. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood, 2007, 109, 2565-70. (Pubitemid 46425903)
108. Belloni, D.; Veschini, L.; Foglieni, C.; Dell'Antonio, G.; Caligaris-Cappio, F.; Ferrarini, M.; Ferrero, E. Bortezomib induces autophagic death in proliferating human endothelial cells. Exp. Cell Res., 2010, 316, 1010-8.
109. Tamura, D.; Arao, T.; Tanaka, K.; Kaneda, H.; Matsumoto, K.; Kudo, K.; Aomatsu, K.; Fujita, Y.; Watanabe, T.; Saijo, N.; Kotani, Y., Nishimura, Y.; Nishio, K. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Sci., 2010, 101, 1403-8.
110. Gozuacik, D.; Kimchi, A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene, 2004, 23, 2891-2906. (Pubitemid 38638851)
111. Kroemer, G.; Jäättelä, M. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer, 2005, 5, 886-897. (Pubitemid 41746033)
112. Lum, J. J.; Bauer, D. E.; Kong, M.; Harris, M. H.; Li, C.; Lindsten, T.; Thompson, C. B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell, 2005, 120, 237-248. (Pubitemid 40174766)
113. Levine, B.; Mizushima, N.; Virgin, H. W. Autophagy in immunity and inflammation. Nature, 2011, 469, 323-35.
114. Wang, Q.; Liang, B.; Shirwany, N. A.; Zou, M. H. 2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen speciesmediated activation of the AMP-activated protein kinase. PLoS One, 2011, 6, e17234.
115. González-Polo, R. A.; Boya, P.; Pauleau, A. L.; Jalil, A.; Larochette, N.; Souquère, S.; Eskelinen, E. L.; Pierron, G.; Saftig, P.; Kroemer, G. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J. Cell Sci., 2005, 118, 3091-3102. (Pubitemid 41149913)
116. Mazzone, M.; Dettori, D.; Leite de Oliveira, R.; Loges, S.; Schmidt, T.; Jonckx, B.; Tian, Y. M.; Lanahan, A. A.; Pollard, P.; Ruiz de Almodovar, C.; De Smet, F.; Vinckier, S.; Aragonés, J.; Debackere, K.; Luttun, A.; Wyns, S.; Jordan, B.; Pisacane, A., Gallez, B.; Lampugnani, M. G., Dejana, E., Simons, M.; Ratcliffe, P.; Maxwell, P.; Carmeliet, P. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell, 2009, 136, 839-51.
117. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005, 307, 58-62. (Pubitemid 40093472)
118. Veschini, L.; Crippa, L.; Dondossola, E.; Doglioni, C.; Corti, A.; Ferrero, E. The vasostatin-1 fragment of Chromogrnin A preserves a quiescent phenotype in hypoxia-driven endothelial cells and regulates tumor neovascularization. FASEB J., In press.
119. Calvani, M.; Rapisarda, A.; Uranchimeg, B.; Shoemaker, R. H.; Melillo, G. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood, 2006, 107, 2705-12.
120. Moschetta, M.; Di Pietro, G.; Ria, R.; Gnoni, A.; Mangialardi, G.; Guarini, A.; Ditonno, P.; Musto, P.; D'Auria, F., Ricciardi, M. R.; Dammacco, F.; Ribatti, D.; Vacca, A. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur. J. Cancer, 2010, 46, 420-429.
121. Mariani, S.; Muraro, M.; Pantaleoni, F.; Fiore, F.; Nuschak, B.; Peola, S.; Foglietta, M.; Palumbo, A.; Coscia, M.; Castella, B.; Bruno, B.; Bertieri, R.; Boano, L.; Boccadoro, M.; Massaia, M. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia, 2005, 19, 664-70. (Pubitemid 40521173)
122. Quach, H.; Ritchie, D.; Stewart, A. K.; Neeson, P.; Harrison, S.; Smyth M. J.; Prince H. M. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia, 2010, 24, 22-32.
123. Melchert, M.; List, A. The thalidomide saga. Int. J. Biochem. Cell Biol., 2007, 39, 1489-99. (Pubitemid 47031027)
124. Sampaio, E. P.; Sarno, E. N.; Galilly, R.; Cohn, Z. A.; Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med., 1991, 173, 699-703.
125. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U S A, 1994, 91, 4082-5. (Pubitemid 24139577)
126. Haslett, P. A.; Corral, L. G.; Albert, M.; Kaplan, G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med., 1998, 187, 1885-1892. (Pubitemid 28262451)
127. Bartlett, J. B.; Dredge, K.; Dalgleish, A. G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer, 2004, 4, 314-22. (Pubitemid 38525287)
128. Li, S.; Gill, N.; Lentzsch, S. Recent advances of IMiDs in cancer therapy. Curr. Opin. Oncol., 2010, 22, 579-85.
129. Higgs, G. Is PDE4 too difficult a drug target? Curr. Opin. Investig. Drugs, 2010, 11, 495-8.
130. Richardson, P. G.; Schlossman, R. L.; Weller, E.; Hideshima, T.; Mitsiades, C.; Davies, F.; LeBlanc, R.; Catley, L. P., Doss, D.; Kelly, K.; McKenney, M.; Mechlowicz, J.; Freeman, A.; Deocampo, R.; Rich, R.; Ryoo, J. J., Chauhan, D.; Balinski, K.; Zeldis, J.; Anderson, K. C. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, 100, 3063-3067. (Pubitemid 35217050)
131. List, A.; Kurtin, S.; Roe, D. J.; Buresh, A.; Mahadevan, D.; Fuchs, D.; Rimsza, L.; Heaton, R.; Knight, R.; Zeldis, J. B. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med., 2005, 352, 549-57. (Pubitemid 40204668)
132. Schey, S. A.; Jones, R. W.; Raj, K.; Streetley, M. A phase I study of an immunomodulatory drug (CC-4047), a structural analogue of thalidomide, in relapsed/refractory multiple myeloma. Exxp. Hematol., 2002, 30, 280.
133. Lacy, M. Q.; Allred, J. B.; Gertz, M. A.; Hayman, S. R., Detweiler Short, K.; Buadi, F.; Dispenzieri, A.; Kumar, S.; Greipp, P. R., Lust, J. A.; Russell, S. J.; Dingli, D.; Zeldenrust, S.; Fonseca, R.; Bergsagel, P. L.; Roy, V.; Stewart, A. K.; Laumann, K.; Mandrekar, S. J.; Reeder, C.; Rajkumar, S. V.; Mikhael, J. R. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in
134. Dredge, K.; Marriott, J. B.; Macdonald, C. D.; Man, H. W.; Chen, R.; Muller, G. W.; Stirling, D.; Dalgleish, A. G. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. B r. J. Cancer, 2002, 87, 1166-72. (Pubitemid 35418112)
135. Kotla, V.; Goel, S.; Nischal, S.; Heuck, C.; Vivek, K.; Das, B.; Verma, A. Mechanism of action of lenalidomide in hematological malignancies. J. Hematol. Oncol., 2009, 2, 36.
136. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Chauhan, D.; Richardson, P. G.; Hideshima, T.; Munshi, N. C.; Treon, S. P.; Anderson, K. C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 2002, 99, 4525-30. (Pubitemid 34627223)
137. Reske, T.; Fulciniti, M.; Munshi, N. C. Mechanism of action of immunomodulatory agents in multiple myeloma. Med. Oncol., 2010, 27 Suppl 1:S7-13.
138. Dredge, K.; Marriott, J. B.; Todryk, S. M.; Muller, G. W., Chen, R., Stirling, D. I.; Dalgleish, A. G. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol., 2002, 168, 4914-9. (Pubitemid 34495953)
139. D'Amato, R. J., Lentzsch, S.; Anderson, K. C.; Rogers, M. S. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin. Oncol., 2001, 28, 597-601. (Pubitemid 33134418)
140. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J., Barlogie, B. Antitumour activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 1999, 341, 1565-1571.
141. Kumar, S.; Witzig, T. E.; Dispenzieri, A.; Lacy, M. Q.; Wellik, L. E.; Fonseca, R.; Lust, J. A.; Gertz, M. A., Kyle, R. A.; Greipp, P. R., Rajkumar, S. V. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia, 2004, 18, 624-627. (Pubitemid 38425879)
142. Dredge, K.; Horsfall, R.; Robinson, S. P.; Zhang, L. H.; Lu, L., Tang, Y.; Shirley, M. A.; Muller, G.; Schafer, P.; Stirling, D.; Dalgleish, A. G., Bartlett, J. B. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc. Res., 2005, 69, 56-63. (Pubitemid 40410468)
143. Lu, L.; Payvandi, F.; Wu, L.; Zhang, L. H.; Hariri, R. J.; Man, H. W.; Chen, R. S.; Muller, G. W.; Hughes, C. C.; Stirling, D. I.; Schafer, P. H.; Bartlett, J. B. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc. Res., 2009, 77, 78-86.
144. De Luisi, A.; Ferrucci, A.; Coluccia, A. M.; Ria, R.; Moschetta, M.; de Luca, E.; Pieroni, L.; Maffia, M.; Urbani, A.; Di Pietro, G.; Guarini, A.; Ranieri, G.; Ditonno, P.; Berardi, S.; Caivano, A.; Basile, A.; Cascavilla, N.; Capalbo, S.; Quarta, G.; Dammacco, F.; Ribatti, D.; Vacca, A. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin. Cancer Res., 2011, 17, 1935-46.
145. Zhang, H.; Vakil, V.; Braunstein, M.; Smith, E. L.; Maroney, J.; Chen, L.; Dai, K.; Berenson, J. R.; Hussain, M. M.; Klueppelberg, U.; Norin, A. J.; Akman, H. O.; Ozçelik, T.; Batuman, O. A. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood, 2005, 105, 3286-94.
146. Pruneri, G.; Ponzoni, M.; Ferreri, A. J.; Decarli, N.; Tresoldi, M.; Raggi, F.; Baldessari, C.; Freschi, M.; Baldini, L.; Goldaniga, M.; Neri, A.; Carboni, N., Bertolini, F.; Viale, G. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br. J. Haematol., 2002, 118, 817-20. (Pubitemid 35007388)
147. Joshi, S.; Khan, R.; Sharma, M.; Kumar, L.; Sharma, A. Angiopoietin-2: a potential novel diagnostic marker in multiple myeloma. Clin. Biochem., 2011, 44, 590-5.
148. Mancuso, P., Bertolini, F. Circulating endothelial cells as biomarkers in clinical oncology. Microvasc. Res., 2010, 79, 224-8.
149. Marcus, C. D.; Ladam-Marcus, V., Cucu, C.; Bouché, O.; Lucas, L.; Hoeffel, C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit. Rev. Oncol. Hematol., 2009, 72, 217-38.
150. Moulopoulos, L. A.; Dimopoulos, M. A.; Christoulas, D.; Kastritis, E.; Anagnostou, D., Koureas, A., Roussou, M.; Gavriatopoulou, M.; Migkou, M.; Iakovaki, M.; Gkotzamanidou, M.; Tasidou, A.; Terpos, E. Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia, 2010, 24, 1206-12.
151. Ramakrishnan, V.; Timm, M.; Haug, J. L.; Kimlinger, T. K.; Wellik, L. E.; Witzig, T. E.; Rajkumar, S. V.; Adjei, A. A.; Kumar, S. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene, 2010, 29, 1190-202.
152. De Bock, K.; De Smet, F.; Leite De Oliveira, R.; Anthonis, K.; Carmeliet, P. Endothelial oxygen sensors regulate tumor vessel abnormalization by instructing phalanx endothelial cells. J. Mol. Med., 2009, 87, 561-9.